In vitro studies on the oxidative metabolism of 20(S)-ginsenoside Rh2 in human, monkey, dog, rat, and mouse liver microsomes, and human liver S9

Drug Metabolism and Disposition

Volumn 40, Issue 10, 2012, Pages 2041-2053

  Li, Liang ^a   Chen, Xiaoyan ^a   Zhou, Jialan ^a   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CARBOXYLIC ACID; CYTOCHROME P450 3A4; DRUG METABOLITE; EPOXIDE; GINSENOSIDE RH 2;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME MECHANISM; EPOXIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE DEHYDROGENATION; OXYGENATION; PRIORITY JOURNAL; RAT;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; ENZYME INHIBITORS; EPOXY COMPOUNDS; GINSENOSIDES; HUMANS; LIVER; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; MACACA FASCICULARIS; RATTUS;

EID: 84866448645     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046995     Document Type: Article

References (27)

1. Baillie TA and Rettie AE (2011) Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 26:15-29.
2. Benet LZ, Broccatelli F, and Oprea TI (2011) BDDCS applied to over 900 drugs. AAPS J 13:519-547.
3. Chen Q, Doss GA, Tung EC, Liu W, Tang YS, Braun MP, Didolkar V, Strauss JR, Wang RW, Stearns RA, et al. (2006) Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos 34:145-151. (Pubitemid 43042656)
4. Cheng CC, Yang SM, Huang CY, Chen JC, Chang WM, and Hsu SL (2005) Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol 55:531-540.
5. Deng P, Zhong D, Xie C, and Chen X (2009) Metabolism investigation of ginsenoside Rh2 in rat using UPLC/Q-TOF MS. J Chin Mass Spectrom Soc 30:83-85.
6. Deng P, You T, Chen X, Yuan T, Huang H, and Zhong D (2011) Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography/quadrupole time-offlight mass spectrometry. Drug Metab Dispos 39:1058-1069.
7. Evans DC and Baillie TA (2005) Minimizing the potential for metabolic activation as an integral part of drug design. Curr Opin Drug Discov Devel 8:44-50. (Pubitemid 40116329)
8. Ham YM, Chun KH, Choi JS, Kim DH, and Lee SK (2003) SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis. Biochem Biophys Res Commun 304:358-364.
9. Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, Bush JA, and Li G (2004) Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82:431-437. (Pubitemid 39388382)
10. Jin J, Shahi S, Kang HK, van Veen HW, and Fan TP (2006) Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345:1308-1314. (Pubitemid 43817877)
11. Kikuchi Y, Sasa H, Kita T, Hirata J, Tode T, and Nagata I (1991) Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 2:63-67.
12. Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, and Taniyama T (1983) [Chemical studies of crude drugs (1). Constituents of Ginseng radix rubra]. Yakugaku Zasshi 103:612-622.
13. Kumar S, Kassahun K, Tschirret-Guth RA, Mitra K, and Baillie TA (2008) Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Curr Opin Drug Discov Devel 11:43-52.
14. Lam JP, Mays DC, and Lipsky JJ (1997) Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram. Biochemistry 36:13748-13754. (Pubitemid 27481625)
15. Li L, Chen X, Li D, and Zhong D (2011) Identification of 20(S)-protopanaxadiol metabolites in human liver microsomes and human hepatocytes. Drug Metab Dispos 39:472-483.
16. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894. (Pubitemid 44911538)
17. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
18. Park JA, Lee KY, Oh YJ, Kim KW, and Lee SK (1997) Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett 121:73-81. (Pubitemid 27504317)
19. Smith DA (1994) Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur J Drug Metab Pharmacokinet 19:193-199.
20. Wang Z, Zheng Q, Liu K, Li G, and Zheng R (2006) Ginsenoside Rh(2) enhances antitumour activity and decreases genotoxic effect of cyclophosphamide. Basic Clin Pharmacol Toxicol 98:411-415.
21. Weinander R, Anderson C, and Morgenstern R (1994) Identification of N-acetylcysteine as a new substrate for rat liver microsomal glutathione transferase. A study of thiol ligands. J Biol Chem 269:71-76.
22. Wen B and Fitch WL (2009) Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry. J Mass Spectrom 44:90-100.
23. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
24. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, and Guns ES (2006) Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol 175:1926-1931.
25. Yang Z, Gao S, Wang J, Yin T, Teng Y, Wu B, You M, Jiang Z, and Hu M (2011) Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 39:1866-1872.
26. Yao Y, Han W, Zhou Y, Li Z, Li Q, Li X, Chen X, and Zhong D (2007) The inhibition effect of 20(S)-protopanaxadiol (PPD) and ginsenoside Rh2 for CYP2C9 and CYP3A4. Polymer 48:2644-2648. (Pubitemid 46560761)
27. Zhang J, Zhou F, Wu X, Gu Y, Ai H, Zheng Y, Li Y, Zhang X, Hao G, Sun J, et al. (2010) 20(S)-Ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab Dispos 38:2179-2187.